海吉亚医疗(06078.HK)与控股股东组合营 设云南省开远解化医院
海吉亚医疗(06078.HK)公布,全资附属伽玛星科技与由控股股东朱义文与其女儿朱剑乔之向上投资就拟成立合营企业订立合营协议,设云南省开远解化医院。
根据合营协议,伽玛星科技及向上投资同意分别出资500万元人民币(下同)及214.29万元,分别占合营企业注册资本总额的70%及30%。
伽玛星科技及向上投资按照其各自於开远解化医院的举办人权益相同的比例成立合营企业,是开远解化医院进行营利性改制的一步。合营企业将为经营该营利性医院的法律实体。
公司看好开远市的肿瘤医疗市场潜力,并拟进一步开发开远解化医院肿瘤业务,以更有效为肿瘤患者提供服务。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.